About: Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19
Creator	Wang, Yan Cheng, Hao Wang, Gui-Qiang
Source	Medline; PMC
abstract	This article reviews the correlation between angiotensin‐converting enzyme 2 (ACE2) and severe risk factors for coronavirus disease 2019 (COVID‐19) and the possible mechanisms. ACE2 is a crucial component of the renin‐angiotensin system (RAS). The classical RAS ACE‐Ang II‐AT1R regulatory axis and the ACE2‐Ang 1‐7‐MasR counter‐regulatory axis play an essential role in maintaining homeostasis in humans. ACE2 is widely distributed in the heart, kidneys, lungs, and testes. ACE2 antagonizes the activation of the classical RAS system and protects against organ damage, protecting against hypertension, diabetes, and cardiovascular disease. Similar to SARS‐CoV, SARS‐CoV‐2 also uses the ACE2 receptor to invade human alveolar epithelial cells. Acute respiratory distress syndrome (ARDS) is a clinical high‐mortality disease, and ACE2 has a protective effect on this type of acute lung injury. Current research shows that the poor prognosis of patients with COVID‐19 is related to factors such as sex (male), age (>60 years), underlying diseases (hypertension, diabetes, and cardiovascular disease), secondary ARDS, and other relevant factors. Because of these protective effects of ACE2 on chronic underlying diseases and ARDS, the development of spike protein‐based vaccine and drugs enhancing ACE2 activity may become one of the most promising approaches for the treatment of COVID‐19 in the future.
has issue date	2020-04-05(xsd:dateTime)
bibo:doi	10.1002/jmv.25785
bibo:pmid	32221983
has license	cc-by
sha1sum (hex)	b1a800ff7a67d5f65be23614605102d25a473d9d
schema:url	https://doi.org/10.1002/jmv.25785
resource representing a document's title	Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19
has PubMed Central identifier	PMC7317908
has PubMed identifier	32221983
schema:publication	J Med Virol
resource representing a document's body	covid:b1a800ff7a67d5f65be23614605102d25a473d9d#body_text
is schema:about of	named entity 'ACE2' named entity 'mechanisms' named entity 'COVID-19' named entity 'MAINTAINING' named entity 'TESTES' named entity 'HUMAN' named entity 'PROTECTIVE EFFECT' named entity 'ACE2' named entity 'axis' named entity 'secondary' named entity 'hypertension' named entity 'ACE2' named entity 'type' named entity 'diabetes' named entity 'maintaining' named entity 'patients' named entity 'MasR' named entity 'correlation' named entity 'homeostasis' named entity 'AT1R' named entity 'RAS' named entity 'acute lung injury' named entity 'cardiovascular disease' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'kidneys' named entity 'risk factors' named entity 'diabetes' named entity 'COVID-19' named entity 'prognosis' named entity 'ACE2 receptor' named entity 'renin-angiotensin system' named entity 'ACE2' named entity 'bird flu' named entity 'SARS-CoV-2' named entity 'common cold' named entity 'ACE2' named entity 'RAS' named entity 'losartan' named entity 'angiotensin-converting enzyme 2' named entity 'physiological effect' named entity 'infection' named entity 'wild-type' named entity 'ACE2' named entity 'mesangial' named entity 'SARS-CoV' named entity 'ACEIs' named entity 'KO mice' named entity 'intestinal epithelial cells' named entity 'renal tubular' named entity 'nasopharynx' named entity 'ACE2' named entity 'COVID' named entity 'ACE2' named entity 'animal experiments' named entity 'receptor' named entity 'blood pressure' named entity 'ACE2' named entity 'hepatocytes' named entity 'cardiovascular disease' named entity 'recombinant' named entity 'proteinuria' named entity 'atherosclerosis' named entity 'atherogenic' named entity 'ACE2' named entity 'coronavirus infections' named entity 'alveolar epithelial cells' named entity 'SARS' named entity 'acute lung injury' named entity 'ACE2' named entity 'cardiovascular disease' named entity 'ACE2' named entity 'ACE2' named entity 'spike protein' named entity 'ACE2' named entity 'infusion' named entity 'Ang II' named entity 'lung function' named entity 'ACE2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software